%0 Journal Article %1 Pfreundschuh.2004 %A Pfreundschuh, Michael %A Trümper, Lorenz %A Kloess, Marita %A Schmits, Rudolf %A Feller, Alfred C. %A Rübe, Christian %A Rudolph, Christian %A Reiser, Marcel %A Hossfeld, Dieter K. %A Eimermacher, Hartmut %A Hasenclever, Dirk %A Schmitz, Norbert %A Loeffler, Markus %D 2004 %J Blood %K IMISE-Publikationen %N 3 %P 634–641 %T Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL %V 104 %X Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. To determine whether biweekly CHOP (CHOP-14) with or without etoposide is more effective than CHOP-21, 689 patients ages 61 to 75 years were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m2 days 1-3), or CHOEP-14. Patients in the 2-weekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extranodal disease. Complete remission rates were 60.1\% (CHOP-21), 70.0\% (CHOEP-21), 76.1\% (CHOP-14), and 71.6\% (CHOEP-14). Five-year event-free and overall survival rates were 32.5\% and 40.6\%, respectively, for CHOP-21 and 43.8\% and 53.3\%, respectively, for CHOP-14. In a multivariate analysis, the relative risk reduction was 0.66 (P =.003) for event-free and 0.58 (P <.001) for overall survival after CHOP-14 compared with CHOP-21. Toxicity of CHOP-14 and CHOP-21 was similar, but CHOEP-21 and in particular CHOEP-14 were more toxic. Due to its favorable efficacy and toxicity profile, CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma.

@article{Pfreundschuh.2004, abstract = {Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for aggressive lymphomas. To determine whether biweekly CHOP (CHOP-14) with or without etoposide is more effective than CHOP-21, 689 patients ages 61 to 75 years were randomized to 6 cycles of CHOP-21, CHOP-14, CHOEP-21 (CHOP plus etoposide 100 mg/m2 days 1-3), or CHOEP-14. Patients in the 2-weekly regimens received granulocyte colony-stimulating factor (G-CSF) starting from day 4. Patients received radiotherapy (36 Gy) to sites of initial bulky disease and extranodal disease. Complete remission rates were 60.1\% (CHOP-21), 70.0\% (CHOEP-21), 76.1\% (CHOP-14), and 71.6\% (CHOEP-14). Five-year event-free and overall survival rates were 32.5\% and 40.6\%, respectively, for CHOP-21 and 43.8\% and 53.3\%, respectively, for CHOP-14. In a multivariate analysis, the relative risk reduction was 0.66 (P =.003) for event-free and 0.58 (P <.001) for overall survival after CHOP-14 compared with CHOP-21. Toxicity of CHOP-14 and CHOP-21 was similar, but CHOEP-21 and in particular CHOEP-14 were more toxic. Due to its favorable efficacy and toxicity profile, CHOP-14 should be considered the new standard chemotherapy regimen for patients ages 60 or older with aggressive lymphoma.}, added-at = {2014-10-15T15:04:16.000+0200}, author = {Pfreundschuh, Michael and Trümper, Lorenz and Kloess, Marita and Schmits, Rudolf and Feller, Alfred C. and Rübe, Christian and Rudolph, Christian and Reiser, Marcel and Hossfeld, Dieter K. and Eimermacher, Hartmut and Hasenclever, Dirk and Schmitz, Norbert and Loeffler, Markus}, biburl = {https://www.bibsonomy.org/bibtex/2e66b967d638ff83230e89d672ec0a5dc/drtester}, interhash = {99a62e82ccc8635b12cab929fc54dd79}, intrahash = {e66b967d638ff83230e89d672ec0a5dc}, journal = {Blood}, keywords = {IMISE-Publikationen}, number = 3, pages = {634–641}, timestamp = {2014-10-15T15:04:16.000+0200}, title = {Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL}, volume = 104, year = 2004 }